Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Your question is unsurprisingly ludicrous. If we had asked you what Cytosorbents was selling their filter for, while they were in the development stage, you would have no answer either. Go slide back under your rock.
Thanks for exemplifying my point. You are one class act Paulness
Wow Paulness, you really are a d*ck!!
I agree Jeff, just hope it doesn't take too long...been here long enough so I can wait for a few more months
SEE YA (you really know your stuff--not)
Viruses aren't treated with antibiotics--is it a virus or a bacteria? If a virus, it has to be an envelope virus for the HP to capture.
They have never stated the prototype would be unveiled at today's meeting. Today's meeting was to finalize the spinoff of the gold company. The last news release on their website dated 2/2 stated this...
“We expect our prototype to be complete in the coming weeks and we'll be sharing news about testing,” said Kal Malhi, President of Cannabix Technologies Inc. "Our team is working hard to deliver a prototype for trial testing as quickly as possible."
swedish company
only pro subscribers can access this article, can you post it here?
I'm well aware of that year old news--from that you conclude that AEMD is out?
Where does it says Aethlon is out? Show me evidence of your claim that Aethlon is no longer part of the DARPA project.
Did you know that Batelle is and always has been the lead on this project, and that AEMD has been and STILL IS a sub-contractor to Batelle?
Talk about disingenuous, get your facts straight before you start spewing.
The key date to watch for will be the ex-date...this is when Cannabix will begin trading without the gold property...anyone holding the stock prioir to the ex-date will get shares in the new entity...
same accounting applies for a spinoff, which this is
No panties in a wad it was just your arrogant response. Here you go...
HomeMarketsSplits CalendarSplit AlertsEducation CenterBlogContact Us
Stock Split Record Date
Why does your stock split calendar not list the record date? (August 17, 2007)
You will not find a record date on our stock split calendar because the record date is meaningless. Here's a definition of "record date": The record date is a date, set by the issuing company, on which an individual must own shares to be eligible to receive a declared dividend or capital gains distribution. With regard to stock splits, the record date is used for accounting purposes only and has no significance to individual investors. Your shares will split as long as you bought them before the ex-date (also known as ex-dividend date).
Again, the record date is meaningless. Don't concern yourself with the terminology. It's simply an "accounting thing" with the company. The split will take care of itself. There is nothing to ever worry about. In its very simplest form, assume a stock is trading around $100 and is to split 2-1. If you pay $100 for the stock AND you still hold it when it actually splits, (ie, when it starts trading at about $50 --assuming it hasn't fallen in price dramatically), then you can be assured that you will receive the "extra" shares. However, if you pay $50 for the stock, then you know that the shares have already split.
So, why even state a "shareholder of record" date?
The "shareholder of record" date goes back to the time when most shares were held individually as paper certificates. On the record date, the company would actually send a certificate to the shareholder for the additional number of shares created by the split. Today, most of us hold shares in a brokerage account. The broker, then, is the owner of record. The additional split shares are distributed to our broker, who will transfer them to our account. The paperwork involved for shares bought or sold between the date of record and the payable date is usually handled between the company or its transfer agent and the broker.
I don't need to prove anything to you, you'll find out soon enough
Though the record date for the spin-off of the gold mining company was stated to be 1/5, due to the way this stuff is accounted for and the fact that the price per share has not yet reflected the spinoff, THERE IS STILL TIME TO GET YOUR POISITIONS IN ORDER TO RECEIVE SHARES in the spun-off mining company.
more info here...http://www.cannabixtechnologies.com/monster-lake-south-gold.html
Instead of b*tching to us here and on the Yahoo board, do something constructive and send Joyce an e-mail asking him why we aren't helping more over there.
ok, I'll go with that
The tech may be different but LCTC is developing a marijuana breathalyzer, so how is it so completely different? There's room for more than one company in the market .
What does the tweet say? Market cap is only $25 million at 40 cents, which is only half the current market cap of their competitor LCTC
No way that's us--ours is a safety study anyway, not efficacy....yet
Even at 30 cents the market cap is under $20 million~~~~no-brainer
10-k out yesterday too...actually better looking balance sheet than ever in last 10 years but yea no buyers these days
I have submitted this to the Chairman's Blog this morning...
February 11, 2015 - 8:10 am
As an ex-NFL football player, you have expressed the personal nature which the subject of CTE–Chronic traumatic encephalopathy–has for you. The subject was again back in the news recently with the announcement that Tony Dorsett is now battling this condition.
Is Aethlon through its Exosome Sciences subsidiary still involved with the Boston University CTE Center in working to develop a test to detect this condition while the subjects are still alive and can be treated? If so, when can we expect some updates on this endeavor?
I have submitted this to the Chairman;s Blog this morning...
February 11, 2015 - 8:10 am
As an ex-NFL football player, you have expressed the personal nature which the subject of CTE–Chronic traumatic encephalopathy–has for you. The subject was again back in the news recently with the announcement that Tony Dorsett is now battling this condition.
Is Aethlon through its Exosome Sciences subsidiary still involved with the Boston University CTE Center in working to develop a test to detect this condition while the subjects are still alive and can be treated? If so, when can we expect some updates on this endeavor?
- See more at: http://www.thechairmansblog.com/aethlon-medical/james-joyce/launch-clinical-program-re-thinks-treatment-viral-pathogens/#comment-307
Jeez man, sell the stock and move on...there's lots of stocks out there if you can't hang
nice job
thanks craig
Thanks for posting this
Sold some at the high today huh hopesty, dang you are one amazing trader, wow!
Lol hopester, now you're getting cartoonish, they should pay you well.
So why are you posting here several times a day every day with your caplock on with your negative posts? You're expending all your energy to do us a favor and save us money? Lol
Looks like the FDA is in on the Aethlon scam lol
I guess you didn't know, but your caps lock is stuck in the on position
Market cap $180 million, the stock is pricing in huge sales increases...very risk to buy at these levels, the downside potential way outpaces the upside at these levels
Results from this study coming in January...
Aethlon, Boston University CTE Center partner to advance blood-based diagnostic candidate
29 September 2014
Aethlon Medical and its diagnostic subsidiary Exosome Sciences (ESI) have entered into a clinical collaboration with the Boston University (BU) CTE Center to advance a blood-based diagnostic candidate to detect chronic traumatic encephalopathy (CTE).
CTE has been found at autopsy in former National Football League (NFL) players and it affects boxers, football players and other athletes who have a history of repetitive brain trauma.
It is a progressive neurodegenerative disorder and can only be diagnosed through postmortem autopsy.
Aethlon develops targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders, while its subsidiary ESI is focused on developing exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders.
Earlier this year, ESI researchers successfully isolated exosome-based biomarkers transporting tau protein across the blood-brain barrier and into the circulatory system.
According to the company, the hallmark of CTE is an excess of accumulation of tau in the brain.
BU CTE Center director of Clinical Research Dr Robert Stern is leading a study, in which researchers from ESI are assessing and defining exosome and exosomal tau populations in blood samples collected from participants enrolled in the DETECT study, which is the first research project on CTE ever.
"Our colleagues at the CTE Center are premier thought leaders in the CTE field and have been instrumental in changing how the NFL and other high-risk sports respond to head trauma."
The Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests (DETECT) trial is funded by the National Institutes of Health (NIH), with support from the National Institute of Neurologic Diseases and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute of Child Health and Human Development (NICHD).
The study is aimed at developing methods, including blood-based tests that could diagnose CTE during life.
Former NFL players aged 40-69 years and same-age control athletes who played non-contact sports were enrolled in the study.
Aethlon Medical CEO and ESI executive chairman Jim Joyce said: "Our colleagues at the CTE Center are premier thought leaders in the CTE field and have been instrumental in changing how the NFL and other high-risk sports respond to head trauma.
"We are truly grateful for the opportunity to establish a blood-based test that could identify CTE in living individuals."
Aethlon's lead product is the Aethlon Hemopurifier that selectively targets the rapid elimination of circulating viruses and tumour-secreted exosomes that promote cancer progression.
Garydemon why are you here bashing AEMD? What is your motive?
CTSO now too thinly traded to attract serious institutional investment. In order to get the stock above $5 stock Chan went for 1 for 25 reverse, resulting in too few shares in the float. This will backfire now.
CTSO market cap $170 million, sales not near enough to sustain this valuation...now is not the time to be buying. It will take at least several quarters of substantially increased sales to justify such a lofty valuation.
What e-mail?